AP2011005978A0 - 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. - Google Patents
2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.Info
- Publication number
- AP2011005978A0 AP2011005978A0 AP2011005978A AP2011005978A AP2011005978A0 AP 2011005978 A0 AP2011005978 A0 AP 2011005978A0 AP 2011005978 A AP2011005978 A AP 2011005978A AP 2011005978 A AP2011005978 A AP 2011005978A AP 2011005978 A0 AP2011005978 A0 AP 2011005978A0
- Authority
- AP
- ARIPO
- Prior art keywords
- diaminopyrimidines
- excessive
- treatment
- cell proliferation
- abnormal cell
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09161496 | 2009-05-29 | ||
| EP10161628 | 2010-04-30 | ||
| PCT/EP2010/057408 WO2010136559A1 (en) | 2009-05-29 | 2010-05-28 | 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2011005978A0 true AP2011005978A0 (en) | 2011-12-31 |
Family
ID=42289495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2011005978A AP2011005978A0 (en) | 2009-05-29 | 2010-05-28 | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8410126B2 (pt) |
| EP (1) | EP2435411B1 (pt) |
| JP (1) | JP5756799B2 (pt) |
| KR (1) | KR20120135010A (pt) |
| CN (1) | CN102448943A (pt) |
| AP (1) | AP2011005978A0 (pt) |
| AR (1) | AR076620A1 (pt) |
| AU (1) | AU2010251943A1 (pt) |
| BR (1) | BRPI1014994A2 (pt) |
| CA (1) | CA2763700A1 (pt) |
| CL (1) | CL2011003022A1 (pt) |
| CO (1) | CO6470899A2 (pt) |
| EA (1) | EA201101674A1 (pt) |
| EC (1) | ECSP11011558A (pt) |
| IL (1) | IL216084A0 (pt) |
| MA (1) | MA33302B1 (pt) |
| MX (1) | MX2011012643A (pt) |
| PE (1) | PE20120370A1 (pt) |
| SG (1) | SG176599A1 (pt) |
| TW (1) | TW201107308A (pt) |
| UY (1) | UY32673A (pt) |
| WO (1) | WO2010136559A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008152195A (ru) * | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3475263B1 (en) | 2016-06-27 | 2022-12-28 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors |
| WO2019190259A1 (ko) * | 2018-03-30 | 2019-10-03 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| EP3972414A4 (en) * | 2019-05-23 | 2023-07-26 | Corteva Agriscience LLC | ARYLAMIDINES FUNGICIDES |
| PE20221083A1 (es) | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
| WO2022208454A1 (en) * | 2021-04-02 | 2022-10-06 | Bridge Biotherapeutics, Inc. | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof |
| CN121358482A (zh) * | 2023-06-09 | 2026-01-16 | 艾斯特里昂株式会社 | 用于预防或治疗脑肿瘤的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0301932A3 (en) * | 2000-05-22 | 2007-09-28 | Leo Pharma As | Benzophenones as inhibitors of il-1 beta and tnf-alpha, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| EP1518855B1 (en) * | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| CA2529611C (en) * | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| BRPI0511138A (pt) * | 2004-05-14 | 2007-11-27 | Pfizer Prod Inc | derivados de pirimidina para o tratamento de desenvolvimento celular anormal |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| PE20120006A1 (es) | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| JP5161233B2 (ja) * | 2006-10-19 | 2013-03-13 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 自己免疫疾患の処置のためのｊａｋキナーゼの阻害剤としての２，４−ピリミジンアミン誘導体 |
| SG165655A1 (en) * | 2008-04-16 | 2010-11-29 | Portola Pharm Inc | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
| US8138339B2 (en) * | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
-
2010
- 2010-05-21 US US12/784,813 patent/US8410126B2/en active Active
- 2010-05-28 BR BRPI1014994A patent/BRPI1014994A2/pt not_active Application Discontinuation
- 2010-05-28 CA CA2763700A patent/CA2763700A1/en not_active Abandoned
- 2010-05-28 TW TW099117275A patent/TW201107308A/zh unknown
- 2010-05-28 MX MX2011012643A patent/MX2011012643A/es not_active Application Discontinuation
- 2010-05-28 AP AP2011005978A patent/AP2011005978A0/xx unknown
- 2010-05-28 SG SG2011086790A patent/SG176599A1/en unknown
- 2010-05-28 UY UY0001032673A patent/UY32673A/es not_active Application Discontinuation
- 2010-05-28 WO PCT/EP2010/057408 patent/WO2010136559A1/en not_active Ceased
- 2010-05-28 AU AU2010251943A patent/AU2010251943A1/en not_active Abandoned
- 2010-05-28 EA EA201101674A patent/EA201101674A1/ru unknown
- 2010-05-28 AR ARP100101883A patent/AR076620A1/es unknown
- 2010-05-28 EP EP10724385.9A patent/EP2435411B1/en active Active
- 2010-05-28 JP JP2012512388A patent/JP5756799B2/ja active Active
- 2010-05-28 KR KR1020117031173A patent/KR20120135010A/ko not_active Withdrawn
- 2010-05-28 PE PE2011002012A patent/PE20120370A1/es not_active Application Discontinuation
- 2010-05-28 CN CN2010800234907A patent/CN102448943A/zh active Pending
- 2010-05-28 MA MA34394A patent/MA33302B1/fr unknown
-
2011
- 2011-11-01 IL IL216084A patent/IL216084A0/en unknown
- 2011-11-29 CL CL2011003022A patent/CL2011003022A1/es unknown
- 2011-12-15 CO CO11173252A patent/CO6470899A2/es not_active Application Discontinuation
- 2011-12-27 EC EC2011011558A patent/ECSP11011558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102448943A (zh) | 2012-05-09 |
| US20110130401A1 (en) | 2011-06-02 |
| UY32673A (es) | 2010-12-31 |
| BRPI1014994A2 (pt) | 2016-05-03 |
| SG176599A1 (en) | 2012-01-30 |
| CL2011003022A1 (es) | 2012-07-13 |
| EA201101674A1 (ru) | 2012-06-29 |
| KR20120135010A (ko) | 2012-12-12 |
| CO6470899A2 (es) | 2012-06-29 |
| ECSP11011558A (es) | 2012-01-31 |
| JP5756799B2 (ja) | 2015-07-29 |
| PE20120370A1 (es) | 2012-05-09 |
| TW201107308A (en) | 2011-03-01 |
| JP2012528121A (ja) | 2012-11-12 |
| EP2435411B1 (en) | 2014-10-29 |
| WO2010136559A1 (en) | 2010-12-02 |
| CA2763700A1 (en) | 2010-12-02 |
| AR076620A1 (es) | 2011-06-22 |
| IL216084A0 (en) | 2012-01-31 |
| US8410126B2 (en) | 2013-04-02 |
| AU2010251943A1 (en) | 2011-12-01 |
| MX2011012643A (es) | 2011-12-14 |
| EP2435411A1 (en) | 2012-04-04 |
| MA33302B1 (fr) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2011005978A0 (en) | 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation. | |
| IL260117A (en) | Use of placental cells to treat diseases, syndromes or conditions of the lungs | |
| MY172372A (en) | Compositions and methods for lowering triglycerides | |
| WO2010058032A3 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| AP2010005508A0 (en) | Triazole derivatives useful for the treatment of diseases. | |
| HRP20130357T1 (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases. | |
| MY160241A (en) | 5-alkynyl-pyrimidines | |
| IN2012DN02471A (pt) | ||
| ZA201201222B (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-derivatives,methods for the production thereof and use thereof for treating diseases | |
| IL207193A0 (en) | Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta | |
| AP2011005857A0 (en) | Tablets for combination therapy. | |
| MX2009009190A (es) | Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean. | |
| IL201562A0 (en) | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | |
| WO2010012745A3 (en) | Benzimidazoles | |
| TN2011000531A1 (en) | 5- alkynyl - pyridines | |
| UA103197C2 (uk) | Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами | |
| NZ609924A (en) | Porphyrin treatment of neurodegenerative diseases | |
| WO2010083240A9 (en) | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | |
| EP2387565A4 (en) | 2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| IN2012DN01846A (pt) | ||
| SI2473492T1 (sl) | Postopek za pripravo(1S,4R)-2-oksa-3-azabiciklo(2.2.1)hept-5-enov | |
| TN2011000049A1 (en) | 5-alkynyl-pyrimidines | |
| TN2010000463A1 (en) | Compositions and methods for preparing and using same | |
| HK1168780A (en) | Methods for treating or preventing ophthalmological diseases | |
| TN2010000408A1 (en) | Thiazolyl-dihydro-indazoles |